Several studies have proved that increased circulating FABP4 levels are a promising biomarker predicting heart failure, stroke, and prognosis and mortality in patients with end-stage renal disease, CAD or other critical illnesses [6, 14, 15, 20, 21]. Here, FABP4 is linked to coronary artery disorder.